These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 15113902)

  • 1. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
    Pinter A; Honnen WJ; He Y; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2004 May; 78(10):5205-15. PubMed ID: 15113902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
    Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
    Krachmarov CP; Honnen WJ; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2006 Jul; 80(14):7127-35. PubMed ID: 16809318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.
    Pinter A; Honnen WJ; Kayman SC; Trochev O; Wu Z
    Vaccine; 1998 Nov; 16(19):1803-11. PubMed ID: 9795384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
    Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M
    J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.
    Narayan KM; Agrawal N; Du SX; Muranaka JE; Bauer K; Leaman DP; Phung P; Limoli K; Chen H; Boenig RI; Wrin T; Zwick MB; Whalen RG
    PLoS One; 2013; 8(1):e52732. PubMed ID: 23326351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
    J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
    Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
    He Y; Honnen WJ; Krachmarov CP; Burkhart M; Kayman SC; Corvalan J; Pinter A
    J Immunol; 2002 Jul; 169(1):595-605. PubMed ID: 12077293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
    McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
    J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.